The influence of ACPA status and characteristics on the course of RA. (Q37980340)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22293763%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

The influence of ACPA status and characteristics on the course of RA (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22293763%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22293763%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Rene E Toes

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22293763%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

4

Tom W J Huizinga

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22293763%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1

Annemiek Willemze

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22293763%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

language of work or name

English

0 references

publication date

31 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22293763%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Rheumatology

21 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22293763%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22293763%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22293763%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

144-152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22293763%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. 1939

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

A NEW SERUM FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Anti-keratin antibodies in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

An important step towards completing the rheumatoid arthritis cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Differences in synovial tissue infiltrates between anti–cyclic citrullinated peptide–positive rheumatoid arthritis and anti–cyclic citrullinated peptide–negative rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Reactivity of agalactosyl IgG with rheumatoid factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Complement activation by (auto-) antibodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Fcgamma receptors as regulators of immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Complement activation and inhibition: a delicate balance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

RETRACTED: Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

In the rat, citrullinated autologous fibrinogen is immunogenic but the induced autoimmune response is not arthritogenic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Isotype distribution of ANTI–CYCLIC citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Anti-dsDNA antibody avidity determination by a simple reliable ELISA method for SLE diagnosis and monitoring

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Absence of avidity maturation of autoantibodies to the protein tyrosine phosphatase-like IA-2 molecule and glutamic acid decarboxylase (GAD65) during progression to type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Alfred Baring Garrod (1819-1907).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Anti-CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The ACPA recognition profile and subgrouping of ACPA-positive RA patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Can we accurately predict the development of rheumatoid arthritis in the preclinical phase?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Persistence of mild, early inflammatory arthritis: The importance of disease duration, rheumatoid factor, and the shared epitope

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

31 March 2020

12 December 2020

Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Long-term impact of delay in assessment of patients with early arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The window of opportunity in ACPA-positive rheumatoid arthritis is not explained by ACPA characteristics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: Results from two large early arthritis cohorts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Anti-CCP antibodies: the past, the present and the future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Antibodies to citrullinated -enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.204

The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis.

31 March 2020

1 reference

12 December 2020

DEMONSTRATION OF A NEW ANTINUCLEAR FOR RHEUMATOID ARTHRITIS ANTIBODY (ANTI-RA33) THAT IS HIGHLY SPECIFIC

1 reference

12 December 2020

Proposed diagnostic criteria for rheumatoid arthritis

1 reference

12 December 2020

The University Centre for the study of chronic rheumatism

1 reference

12 December 2020

The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues

1 reference

12 December 2020

The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: do they imply new risk factors?

1 reference

12 December 2020